

Richard F Ambinder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9109257/publications.pdf>

Version: 2024-02-01

309
papers

17,225
citations

12303

69
h-index

18606

119
g-index

313
all docs

313
docs citations

313
times ranked

13849
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 473-485.	2.5	11
2	Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 260-269.	0.2	4
3	Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 259.e1-259.e11.	0.6	11
4	NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 322-334.	2.3	35
5	Significance of lymph node fine needle aspiration for the diagnosis of HIV-associated lymphoma in a low-resource setting. <i>Aids</i> , 2022, 36, 1393-1398.	1.0	2
6	AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 2646-2656.	3.2	8
7	Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection. <i>Transplant Infectious Disease</i> , 2021, 23, e13521.	0.7	18
8	Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma. <i>Haematologica</i> , 2021, 106, 730-735.	1.7	8
9	Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma. , 2021, 9, e002097.		28
10	Arsenicals, the Integrated Stress Response, and Epstein-Barr Virus Lytic Gene Expression. <i>Viruses</i> , 2021, 13, 812.	1.5	5
11	Feasibility of Cell-Free DNA Collection and Clonal Immunoglobulin Sequencing in South African Patients With HIV-Associated Lymphoma. <i>JCO Global Oncology</i> , 2021, 7, 611-621.	0.8	7
12	Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2408-2415.	0.6	2
13	National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2021, 39, 1971-1982.	0.8	90
14	Immune Activation and Microbial Translocation as Prognostic Biomarkers for AIDS-Related Non-Hodgkin Lymphoma in the AMC-034 Study. <i>Clinical Cancer Research</i> , 2021, 27, 4642-4651.	3.2	4
15	Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial. <i>Frontiers in Immunology</i> , 2021, 12, 700045.	2.2	2
16	CloneRetriever: An Automated Algorithm to Identify Clonal B and T Cell Gene Rearrangements by Next-Generation Sequencing for the Diagnosis of Lymphoid Malignancies. <i>Clinical Chemistry</i> , 2021, 67, 1524-1533.	1.5	1
17	Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 863.e1-863.e5.	0.6	4
18	Epstein-Barr Virus-Associated Post-transplant Lymphoproliferative Disease. <i>Recent Results in Cancer Research</i> , 2021, 217, 197-207.	1.8	3

#	ARTICLE	IF	CITATIONS
19	Clonal Hematopoiesis Is More Common in People Living with HIV and May be Associated with Increased Prevalence of Cardiovascular Disease. <i>Blood</i> , 2021, 138, 4298-4298.	0.6	0
20	Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab. <i>Blood</i> , 2021, 138, 1846-1846.	0.6	0
21	Rebound HIV viremia with meningoencephalitis following antiretroviral therapy interruption after allogeneic bone marrow transplant. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, .	0.9	1
22	Plasma EBV DNA: A Promising Diagnostic Marker for Endemic Burkitt Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 804083.	1.3	17
23	Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma. <i>Clinical Cancer Research</i> , 2020, 26, 558-565.	3.2	13
24	Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 502-508.	2.0	9
25	Kaposi's Sarcoma-Associated Herpesvirus LANA Modulates the Stability of the E3 Ubiquitin Ligase RLIM. <i>Journal of Virology</i> , 2020, 94, .	1.5	6
26	Haemopoietic cell transplantation in patients living with HIV. <i>Lancet HIV,the</i> , 2020, 7, e652-e660.	2.1	14
27	Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2075-2081.	2.0	17
28	Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. <i>Lancet HIV,the</i> , 2020, 7, e602-e610.	2.1	11
29	Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2020, 4, 5078-5088.	2.5	23
30	Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. <i>Blood Advances</i> , 2020, 4, 3913-3925.	2.5	52
31	Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. <i>Lancet Haematology,the</i> , 2020, 7, e660-e670.	2.2	86
32	Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2306-2310.	2.0	8
33	Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. <i>Blood Advances</i> , 2020, 4, 1770-1779.	2.5	92
34	Single-cell transcriptional landscapes reveal HIV-1-driven aberrant host gene transcription as a potential therapeutic target. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	75
35	Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). <i>Blood</i> , 2020, 136, 1284-1297.	0.6	39
36	Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1679-1688.	2.0	25

#	ARTICLE	IF	CITATIONS
37	Cytomegalovirus in Adult Allogeneic Blood and Marrow Transplant Patients Before or Around the Period of Neutrophil Recovery: A Single-Center, Retrospective, Descriptive Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa081.	0.4	3
38	Transplantation Using Bone Marrow from a (very) HLA Mismatched Unrelated Donor in the Setting of Post-Transplant Cyclophosphamide Is Feasible and Expands Access to Underserved Minorities. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S283-S284.	2.0	2
39	CpG methylation in cell-free Epstein-Barr virus DNA in patients with EBV-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 1624-1627.	2.5	7
40	Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 755-781.	2.3	94
41	Pharmacologic Activation of Lytic Epstein-Barr Virus Gene Expression without Virion Production. <i>Journal of Virology</i> , 2019, 93, .	1.5	9
42	Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2431-2437.	2.0	54
43	Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2160-2166.	2.0	27
44	Prevalence of HIV in Patients with Malignancy and of Malignancy in HIV Patients in a Tertiary Care Center from North India. <i>Current HIV Research</i> , 2019, 16, 315-320.	0.2	4
45	R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1261-1265.	0.6	14
46	Tâ€cell receptor sequencing demonstrates persistence of virusâ€specific T cells after antiviral immunotherapy. <i>British Journal of Haematology</i> , 2019, 187, 206-218.	1.2	29
47	Is It Time to Revisit the Role of Allogeneic Transplantation in Lymphoma?. <i>Current Oncology Reports</i> , 2019, 21, 65.	1.8	2
48	Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. <i>Lancet Haematology</i> , 2019, 6, e183-e193.	2.2	111
49	AIDS-Related Kaposi Sarcoma, Version 2.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 171-189.	2.3	35
50	Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. <i>Blood Advances</i> , 2019, 3, 2608-2616.	2.5	20
51	Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1128-1135.	2.0	38
52	Allogenic Stem Cell Transplantation for Secondary CNS Lymphoma: A Retrospective Review of 21 Patients. <i>Blood</i> , 2019, 134, 3342-3342.	0.6	3
53	Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085. <i>Blood</i> , 2019, 134, 130-130.	0.6	5
54	Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials. <i>Blood</i> , 2019, 134, 4525-4525.	0.6	1

#	ARTICLE	IF	CITATIONS
55	A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes. <i>Blood</i> , 2019, 134, 1588-1588.	0.6	1
56	A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (allo-BMT) Remission Maintenance. <i>Blood</i> , 2019, 134, 778-778.	0.6	3
57	HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths. <i>Molecular Therapy</i> , 2018, 26, 1435-1446.	3.7	18
58	Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone. <i>Clinical Cancer Research</i> , 2018, 24, 3273-3281.	3.2	20
59	Safety and Preliminary Efficacy of Vorinostat With EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 180-190.e2.	0.2	11
60	Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1022-1028.	2.0	29
61	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1099-1102.	2.0	61
62	NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 245-254.	2.3	45
63	Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 343-352.	2.0	61
64	Hodgkin lymphoma: A review and update on recent progress. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 116-132.	157.7	315
65	Resistance Is Futile: Engineering the Adoptive T-Cell Therapies of the Future. <i>Journal of Clinical Oncology</i> , 2018, 36, 1140-1142.	0.8	0
66	Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. <i>Blood Advances</i> , 2018, 2, 2226-2229.	2.5	47
67	Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas. <i>Blood Advances</i> , 2018, 2, 3618-3626.	2.5	9
68	As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2018, 67, 251-260.	2.9	27
69	Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas. <i>Theranostics</i> , 2018, 8, 61-77.	4.6	33
70	Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 986-1017.	2.3	64
71	Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2056-2064.	2.0	32
72	A viral protein kinase drug target for tumors?. <i>Journal of Clinical Investigation</i> , 2018, 128, 2197-2198.	3.9	3

#	ARTICLE	IF	CITATIONS
73	A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I). <i>Blood</i> , 2018, 132, 679-679.	0.6	13
74	Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). <i>Blood</i> , 2018, 132, 623-623.	0.6	1
75	AMC075: A randomized phase II trial of vorinostat with R-EPOCH in aggressive HIV-related NHL. <i>Journal of Clinical Oncology</i> , 2018, 36, 7573-7573.	0.8	1
76	Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. <i>Haematologica</i> , 2017, 102, 391-400.	1.7	152
77	Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation. <i>Journal of Virology</i> , 2017, 91, .	1.5	23
78	High frequency of identical clonal immunoglobulin DNA in pre-treatment tumor and plasma from untreated patients with HIV-associated lymphoma: prospective multicenter trial of the AIDS malignancies consortium (AMC 064). <i>Leukemia and Lymphoma</i> , 2017, 58, 2939-2942.	0.6	2
79	Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 608-638.	2.3	81
80	HIV-Specific T CELLS Expanded from HIV+ and HIV-Naive Donors Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic HSCT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S194-S195.	2.0	1
81	Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1114-1123.	1.1	20
82	Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. <i>Blood</i> , 2017, 129, 1389-1393.	0.6	69
83	Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1903-1909.	2.0	14
84	Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1887-1894.	2.0	42
85	Plasma Epstein-Barr Virus DNA for Screening. <i>New England Journal of Medicine</i> , 2017, 377, 584-585.	13.9	9
86	Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. <i>Molecular Imaging and Biology</i> , 2017, 19, 429-436.	1.3	12
87	Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 325-332.	2.0	61
88	Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma. <i>Blood Advances</i> , 2017, 1, 681-684.	2.5	27
89	Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2017, 1, 288-292.	2.5	84
90	Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy. <i>Blood Advances</i> , 2017, 1, 1324-1334.	2.5	36

#	ARTICLE	IF	CITATIONS
91	Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity. <i>Journal of Clinical Investigation</i> , 2017, 127, 651-656.	3.9	64
92	Unveiling kaposi sarcoma viral antigens. <i>Oncotarget</i> , 2017, 8, 50325-50326.	0.8	1
93	763. HIV-Specific T Cells Can Be Expanded from Virus-Naive Donors to Target a Range of Viral Epitopes: Implications for a Cure Strategy After Allogeneic HSCT. <i>Molecular Therapy</i> , 2016, 24, S302.	3.7	0
94	The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. <i>Blood</i> , 2016, 127, 2007-2017.	0.6	158
95	Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. <i>Blood</i> , 2016, 128, 1050-1058.	0.6	74
96	EBV, an inhibited receptor kinase, and lymphoma. <i>Blood</i> , 2016, 128, 1542-1543.	0.6	1
97	Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. <i>Scientific Reports</i> , 2016, 6, 26591.	1.6	90
98	Functionally Active HIV-Specific T Cells that Target Gag and Nef Can Be Expanded from Virus-Naive Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 536-541.	2.0	34
99	Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium. <i>Leukemia and Lymphoma</i> , 2016, 57, 1731-1734.	0.6	24
100	The Use of Post-Transplantation Cyclophosphamide after Myeloablative, HLA-Matched Allogeneic Bone Marrow Transplantation Minimizes the Need for Additional Immunosuppression. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S46-S47.	2.0	0
101	Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial). <i>Clinical Cancer Research</i> , 2016, 22, 328-336.	3.2	13
102	Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. <i>Leukemia and Lymphoma</i> , 2016, 57, 666-675.	0.6	11
103	Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E). <i>Blood</i> , 2016, 128, 1106-1106.	0.6	34
104	Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial. <i>Blood</i> , 2016, 128, 2992-2992.	0.6	5
105	Checkpoint Inhibitor Therapy and Graft Versus Host Disease in Allogeneic Bone Marrow Transplant Recipients of Haploidentical and Matched Products with Post-Transplant Cyclophosphamide.. <i>Blood</i> , 2016, 128, 4571-4571.	0.6	15
106	AMC-053: Pilot Study of an Oncolytic Viral Strategy Using Bortezomib with ICE +/- Rituximab for Relapsed/Refractory HIV+ Lymphomas. <i>Blood</i> , 2016, 128, 786-786.	0.6	2
107	Tumor-Infiltrating Macrophages in Post-Transplant, Relapsed Classical Hodgkin Lymphoma Are Donor-Derived. <i>PLoS ONE</i> , 2016, 11, e0163559.	1.1	9
108	Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial. <i>Blood</i> , 2016, 128, 1346-1346.	0.6	12

#	ARTICLE	IF	CITATIONS
109	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. <i>Blood</i> , 2015, 125, 3024-3031.	0.6	259
110	Hodgkin Lymphoma, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 554-586.	2.3	37
111	AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. <i>Blood</i> , 2015, 126, 160-166.	0.6	82
112	Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. <i>Science Translational Medicine</i> , 2015, 7, 288ra78.	5.8	104
113	A Human Immunodeficiency Virus Controller With a Large Population of CD4+CD8+ Double-Positive T Cells. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv039.	0.4	3
114	Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2115-2122.	2.0	26
115	Family history of cancer and risk of pediatric and adolescent Hodgkin lymphoma: A Children's Oncology Group study. <i>International Journal of Cancer</i> , 2015, 137, 2163-2174.	2.3	13
116	Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. <i>Journal of Clinical Oncology</i> , 2015, 33, 3152-3161.	0.8	215
117	Dietary Pattern and Risk of Hodgkin Lymphoma in a Population-Based Case-Control Study. <i>American Journal of Epidemiology</i> , 2015, 182, 405-416.	1.6	17
118	Lymphoproliferative Disease Risk in Patients with Autoimmune Disease: Clustering of Primary CNS Lymphoma with Drug Regimen and Disease Process. <i>Blood</i> , 2015, 126, 1490-1490.	0.6	1
119	Nonmyeloablative (NMA), HLA-Mismatched Unrelated Donor (mMUD) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Has Outcomes Similar to Matched BMT. <i>Blood</i> , 2015, 126, 2002-2002.	0.6	2
120	Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412). <i>Blood</i> , 2015, 126, 585-585.	0.6	25
121	Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation. <i>Oncotarget</i> , 2015, 6, 31018-31029.	0.8	23
122	Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. <i>Oncotarget</i> , 2015, 6, 33849-33866.	0.8	55
123	A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS8602-TPS8602.	0.8	1
124	Using CpG Methylation to Monitor Ebv in Plasma. <i>Annals of Oncology</i> , 2014, 25, v24.	0.6	0
125	Nelfinavir Inhibits Maturation and Export of Herpes Simplex Virus 1. <i>Journal of Virology</i> , 2014, 88, 5455-5461.	1.5	27
126	Serum Levels of Cytokines and Biomarkers for Inflammation and Immune Activation, and HIV-Associated Non-Hodgkin B-Cell Lymphoma Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 343-349.	1.1	57

#	ARTICLE	IF	CITATIONS
127	HHV-8-positive and EBV-positive Intravascular Lymphoma. <i>American Journal of Surgical Pathology</i> , 2014, 38, 426-432.	2.1	32
128	Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting β -catenin and AKT signaling but frequently methylated in common carcinomas. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 2179-2192.	2.4	43
129	Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1797-1803.	0.8	75
130	Infectious, autoimmune and allergic diseases and risk of Hodgkin lymphoma in children and adolescents: A Children's Oncology Group study. <i>International Journal of Cancer</i> , 2014, 135, 1454-1469.	2.3	29
131	Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma. <i>Annals of Hematology</i> , 2014, 93, 1245-1246.	0.8	8
132	Rarity of Donor-Derived Malignancy after Allogeneic BMT with High-Dose Post-Transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S252.	2.0	4
133	Old variables, new value: a refined IPI for DLBCL. <i>Blood</i> , 2014, 123, 800-801.	0.6	4
134	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. <i>Blood</i> , 2014, 124, 3817-3827.	0.6	165
135	A Rise in CNS Lymphoproliferative Disease Incidence Reveals a Protective Role of Calcineurin Inhibitors. <i>Blood</i> , 2014, 124, 3020-3020.	0.6	0
136	Nonmyeloablative HLA-Haploidentical (NMA Haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Is Associated with Similar Outcomes to Matched BMT When Stratified By Disease Risk Index (DRI). <i>Blood</i> , 2014, 124, 680-680.	0.6	2
137	AMC075: The Combination of Vorinostat with Chemotherapy and Rituximab Is Tolerable and Feasible in HIV-Related B-Cell Non-Hodgkin's Lymphoma with High-Risk Features. <i>Blood</i> , 2014, 124, 4473-4473.	0.6	0
138	High Frequency of Identical Lymphoma Clones Detected in Pre-Treatment Tumor and Plasma from Untreated Patients with HIV-Associated Lymphomas: Prospective Multicenter Trial of the AIDS Malignancy Consortium (AMC 064). <i>Blood</i> , 2014, 124, 1680-1680.	0.6	0
139	EBV-Related Lymphomas: New Approaches to Treatment. <i>Current Treatment Options in Oncology</i> , 2013, 14, 224-236.	1.3	70
140	Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1514-1517.	2.0	103
141	Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2563-2564.	0.6	4
142	Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 602-606.	2.0	87
143	Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 483-490.	0.6	13
144	Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 655-657.	0.6	8

#	ARTICLE	IF	CITATIONS
145	Hematopoietic stem cell transplantation in HIV-1-infected individuals. <i>Current Opinion in Oncology</i> , 2013, 25, 180-186.	1.1	12
146	Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention. <i>Current Opinion in Oncology</i> , 2013, 25, 495-502.	1.1	50
147	Serum Levels of the Chemokine CXCL13, Genetic Variation in <i>CXCL13</i> and Its Receptor CXCR5, and HIV-Associated Non-Hodgkin B-Cell Lymphoma Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 295-307.	1.1	49
148	Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1662-1668.	0.8	161
149	Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. <i>Blood</i> , 2013, 121, 3547-3553.	0.6	117
150	Encouraging Outcomes In Older Patients (Pts) Following Nonmyeloablative (NMA) Haploidentical Blood or Marrow Transplantation (haploBMT) With High-Dose Posttransplantation Cyclophosphamide (PT/Cy). <i>Blood</i> , 2013, 122, 158-158.	0.6	3
151	Outcomes Of Nonmyeloablative (NMA) Haploidentical Blood Or Marrow Transplantation (haploBMT) With High-Dose Posttransplantation Cyclophosphamide (PT/Cy) For Lymphoma. <i>Blood</i> , 2013, 122, 2091-2091.	0.6	1
152	Outcomes Of Allogeneic Blood Or Marrow Transplantation (AlloBMT) In Multiple Myeloma With Post-Transplantation Cyclophosphamide (PTCy). <i>Blood</i> , 2013, 122, 3407-3407.	0.6	2
153	A phase IB trial of 5-azacitidine (5AC) and suberoylanilide hydroxamic acid (SAHA) in patients with metastatic or locally recurrent nasopharyngeal carcinoma (NPC) and NK-T cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, e17017-e17017.	0.8	1
154	Incidence of posttransplantation lymphoproliferative disorder (PTLD) following allogeneic blood or marrow transplantation (alloBMT) using post-transplantation cyclophosphamide (PT-Cy) for graft-versus-host disease (GVHD) prophylaxis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7009-7009.	0.8	0
155	Characterizing The CpG Methylation Of Epstein-Barr Virus DNA In The Plasma Of Patients With Hodgkin Lymphoma and HIV-Associated Burkitt Lymphoma. <i>Blood</i> , 2013, 122, 4232-4232.	0.6	0
156	Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients. <i>Blood</i> , 2013, 122, 1785-1785.	0.6	0
157	CpG Methylation as a Tool to Characterize Cell-Free Kaposi Sarcoma Herpesvirus DNA. <i>Journal of Infectious Diseases</i> , 2012, 205, 1095-1099.	1.9	16
158	HIV-1 DNA Is Detected in Bone Marrow Populations Containing CD4+ T Cells but Is not Found in Purified CD34+ Hematopoietic Progenitor Cells in Most Patients on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2012, 205, 1014-1018.	1.9	102
159	A Protein Array Screen for Kaposi's Sarcoma-Associated Herpesvirus LANA Interactors Links LANA to TIP60, PP2A Activity, and Telomere Shortening. <i>Journal of Virology</i> , 2012, 86, 5179-5191.	1.5	56
160	Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 589-597.	2.3	90
161	Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 4129-4132.	0.6	67
162	Plasma viral DNA as a marker of tumor response in EBV(+) Hodgkin lymphoma in a phase III study (E2496).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8003-8003.	0.8	1

#	ARTICLE	IF	CITATIONS
163	Cell-free EBV DNA in Hodgkin lymphoma.. Journal of Clinical Oncology, 2012, 30, 7-7.	0.8	0
164	Nonmyeloablative Allogeneic (Allo) BMT for B-Cell Lymphoma with Posttransplant Rituximab: Donor Selection by Prioritizing FCGR3A-158 Polymorphism Over HLA Matching.. Blood, 2012, 120, 3107-3107.	0.6	0
165	Outcomes of Allogeneic Blood or Marrow Transplantation for Peripheral T-Cell Lymphoma.. Blood, 2012, 120, 3084-3084.	0.6	0
166	High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leukemia and Lymphoma, 2011, 52, 2076-2081.	0.6	8
167	Conserved Herpesvirus Kinases Target the DNA Damage Response Pathway and TIP60 Histone Acetyltransferase to Promote Virus Replication. Cell Host and Microbe, 2011, 10, 390-400.	5.1	148
168	Extended Follow-up of Autologous Bone Marrow Transplantation with 4-Hydroperoxycyclophosphamide (4-HC) Purging for Indolent or Transformed Non-Hodgkin Lymphomas. Biology of Blood and Marrow Transplantation, 2011, 17, 365-373.	2.0	6
169	A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy. Medical Physics, 2011, 38, 2892-2903.	1.6	21
170	Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy. Journal of Clinical Virology, 2011, 51, 195-198.	1.6	9
171	Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncology, The, 2011, 12, 905-912.	5.1	137
172	Clonal immunoglobulin DNA in the plasma of patients with AIDS lymphoma. Blood, 2011, 117, 4860-4862.	0.6	8
173	Bortezomib induction of C/EBP β mediates Epstein-Barr virus lytic activation in Burkitt lymphoma. Blood, 2011, 117, 6297-6303.	0.6	72
174	When differentiation goes viral. Blood, 2011, 117, 5790-5791.	0.6	0
175	Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 1020-1058.	2.3	40
176	Low-Grade Follicular Lymphoma of the Small Intestine: A Challenge for Management. Seminars in Oncology, 2011, 38, 714-720.	0.8	5
177	B-Cell Stimulatory Cytokines and Markers of Immune Activation Are Elevated Several Years Prior to the Diagnosis of Systemic AIDS-Associated Non-Hodgkin B-Cell Lymphoma. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1303-1314.	1.1	125
178	Comparison of Humoral Immune Responses to Epstein-Barr Virus and Kaposi's Sarcoma-Associated Herpesvirus Using a Viral Proteome Microarray. Journal of Infectious Diseases, 2011, 204, 1683-1691.	1.9	33
179	Randomized Phase III Trial of 131iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) Vs. Rituximab/BEAM and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): No Difference in Progression-Free (PFS) or Overall Survival (OS). Blood, 2011, 118, 661-661.	0.6	11
180	IgH gene rearrangements as plasma biomarkers in Non-Hodgkin's Lymphoma patients. Oncotarget, 2011, 2, 178-185.	0.8	61

#	ARTICLE	IF	CITATIONS
181	Nelfinavir Activates Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus Lytic Cycle by Inducing ER Stress. <i>Blood</i> , 2011, 118, 5011-5011.	0.6	4
182	Cancer biomarkers in HIV patients. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 531-537.	1.5	30
183	High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. <i>Blood</i> , 2010, 115, 2136-2141.	0.6	107
184	Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2010, 115, 3008-3016.	0.6	254
185	High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. <i>Blood</i> , 2010, 115, 3224-3230.	0.6	346
186	Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma. <i>Cancer</i> , 2010, 116, 3969-3977.	2.0	138
187	De Novo DNA Methyltransferase DNMT3b Interacts with NEDD8-modified Proteins. <i>Journal of Biological Chemistry</i> , 2010, 285, 36377-36386.	1.6	25
188	Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 482-489.	2.0	260
189	Epigenetic Silencing of a Proapoptotic Cell Adhesion Molecule, the Immunoglobulin Superfamily Member IGSF4, by Promoter CpG Methylation Protects Hodgkin Lymphoma Cells from Apoptosis. <i>American Journal of Pathology</i> , 2010, 177, 1480-1490.	1.9	22
190	Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus Lytic Cycle Induction with Bortezomib Is a Response to ER Stress. <i>Blood</i> , 2010, 116, 1736-1736.	0.6	2
191	High-Dose Cyclophosphamide (Cy), Rituximab, and a Cancer Vaccine for Relapsed Classical Hodgkin's Lymphoma (cHL). <i>Blood</i> , 2010, 116, 3954-3954.	0.6	1
192	Clonal Ig DNA Detection In Plasma From Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2010, 116, 3127-3127.	0.6	0
193	A Proteomic Platform for EBV and KSHV Serological Screening. <i>Blood</i> , 2010, 116, 1747-1747.	0.6	6
194	Effects of Chemotherapy in AIDS-Associated Non-Hodgkin's Lymphoma on Kaposi's Sarcoma Herpesvirus DNA in Blood. <i>Journal of Clinical Oncology</i> , 2009, 27, 2496-2502.	0.8	24
195	Molecular and Clinical Assessment in the Treatment of AIDS Kaposi Sarcoma with Valproic Acid. <i>Clinical Infectious Diseases</i> , 2009, 49, 1946-1949.	2.9	24
196	A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 6241-6249.	3.2	80
197	Evaluation of T- and NK-Cell-Targeted Therapies: Is There a Role for Rituximab Prophylaxis?. <i>Clinical Cancer Research</i> , 2009, 15, 2205-2206.	3.2	2
198	Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 242-248.	2.0	64

#	ARTICLE	IF	CITATIONS
199	Circulating clonotypic B cells in classic Hodgkin lymphoma. <i>Blood</i> , 2009, 113, 5920-5926.	0.6	159
200	Response: Hodgkin lymphoma stem cells. <i>Blood</i> , 2009, 114, 3971-3972.	0.6	3
201	Human T Cell Leukemia Virus Reactivation with Progression of Adult T-Cell Leukemia-Lymphoma. <i>PLoS ONE</i> , 2009, 4, e4420.	1.1	40
202	Efficacy of a Brief, Cyclophosphamide-Intensive Regimen for Older Patients with Newly Diagnosed Burkitt's or Atypical Burkitt's Lymphoma/Leukemia.. <i>Blood</i> , 2009, 114, 2685-2685.	0.6	0
203	Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California populations. <i>International Journal of Cancer</i> , 2008, 123, 1499-1507.	2.3	57
204	Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2008, 32, 1439-1447.	0.4	18
205	Immunotherapies for Hodgkin's lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 135-144.	2.0	9
206	Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. <i>Nature Medicine</i> , 2008, 14, 1118-1122.	15.2	85
207	HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 641-650.	2.0	1,525
208	Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1279-1287.	2.0	251
209	Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance. <i>Cancer Research</i> , 2008, 68, 190-197.	0.4	495
210	Small Capsid Protein pORF65 Is Essential for Assembly of Kaposi's Sarcoma-Associated Herpesvirus Capsids. <i>Journal of Virology</i> , 2008, 82, 7201-7211.	1.5	41
211	Hodgkin twins: double good, double trouble. <i>Blood</i> , 2008, 111, 3310-3310.	0.6	0
212	Imaging Virus-Associated Cancer. <i>Current Pharmaceutical Design</i> , 2008, 14, 3048-3065.	0.9	3
213	Blood and marrow transplant for lymphoma patients with HIV/AIDS. <i>Current Opinion in Oncology</i> , 2008, 20, 201-205.	1.1	11
214	Greater HLA Disparity Is Associated with Reduced Risk of Relapse and Improved Event-Free Survival after Nonmyeloablative, HLA-Haploidentical BMT with Post-Transplantation High-Dose Cyclophosphamide. <i>Blood</i> , 2008, 112, 150-150.	0.6	8
215	Phase I/II Dose-Escalation Study of Tositumomab and Iodine I 131 Tositumomab for Relapsed/Refractory Classical or Lymphocyte-Predominant Hodgkin's Lymphoma: Feasibility and Initial Safety. <i>Blood</i> , 2008, 112, 3059-3059.	0.6	7
216	Post-Transplantation High Dose Cyclophosphamide (Cy) Is Effective Single Agent for Prevention of Acute and Chronic Graft Versus Host Disease after Myeloablative HLA Matched Related and Unrelated Bone Marrow Transplantation (BMT). <i>Blood</i> , 2008, 112, 56-56.	0.6	6

#	ARTICLE	IF	CITATIONS
217	Hodgkin Disease/Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 594.	2.3	9
218	Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab. Clinical Cancer Research, 2007, 13, 2392-2399.	3.2	55
219	Tumor-Specific Methylation of the 8p22 Tumor Suppressor Gene DLC1 is an Epigenetic Biomarker for Hodgkin, Nasal NK/T-Cell and Other Types of Lymphomas. Epigenetics, 2007, 2, 15-21.	1.3	27
220	Virus-Associated Tumor Imaging by Induction of Viral Gene Expression. Clinical Cancer Research, 2007, 13, 1453-1458.	3.2	52
221	Induction of Autologous Graft-versus-Host Disease: Results of a Randomized Prospective Clinical Trial in Patients with Poor Risk Lymphoma. Biology of Blood and Marrow Transplantation, 2007, 13, 1185-1191.	2.0	24
222	Infection of human B cells with Epstein-Barr virus results in the expression of somatic hypermutation-inducing molecules and in the accrual of oncogene mutations. Molecular Immunology, 2007, 44, 934-942.	1.0	80
223	Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. British Journal of Haematology, 2007, 136, 829-832.	1.2	52
224	Epstein-Barr virus-related lymphoproliferative disorders. Current Hematologic Malignancy Reports, 2007, 2, 249-254.	1.2	9
225	Risk-Adapted Therapy of Aggressive Lymphoma Based on FDG-PET Performed after 2 or 3 Cycles of Initial Chemotherapy.. Blood, 2007, 110, 1894-1894.	0.6	2
226	A Pilot Trial of Valproic Acid in Patients with Kaposi's Sarcoma: A Multi-Center Trial of the AIDS Malignancy Consortium.. Blood, 2007, 110, 2279-2279.	0.6	2
227	Aberrant Hedgehog Signaling Represents a Novel Therapeutic Target in B Cell Lymphomas.. Blood, 2007, 110, 3582-3582.	0.6	0
228	Clonal Heavy and Light Chain Immunoglobulin DNA in Plasma/Serum of AIDS Lymphoma Patients.. Blood, 2007, 110, 1579-1579.	0.6	0
229	Graft-versus-Host Reactions and the Effectiveness of Donor Lymphocyte Infusions. Biology of Blood and Marrow Transplantation, 2006, 12, 414-421.	2.0	56
230	Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin's Lymphoma. Biology of Blood and Marrow Transplantation, 2006, 12, 965-972.	2.0	44
231	The kiss that scars. Blood, 2006, 108, 8-8.	0.6	6
232	Hiding in plain sight. Blood, 2006, 108, 2891-2891.	0.6	3
233	Clonotypic B Cells Circulate in Hodgkin's Lymphoma (HL).. Blood, 2006, 108, 470-470.	0.6	6
234	Exposure to childhood infections and risk of Epstein-Barr virus-defined Hodgkin's lymphoma in women. International Journal of Cancer, 2005, 115, 599-605.	2.3	27

#	ARTICLE	IF	CITATIONS
235	Epstein-Barr Virus As a Marker of Survival After Hodgkin's Lymphoma: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 7604-7613.	0.8	155
236	Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. <i>Blood</i> , 2005, 106, 1538-1543.	0.6	390
237	Mononucleosis in the Laboratory. <i>Journal of Infectious Diseases</i> , 2005, 192, 1503-1504.	1.9	21
238	The Stress-Responsive Gene GADD45G Is a Functional Tumor Suppressor, with Its Response to Environmental Stresses Frequently Disrupted Epigenetically in Multiple Tumors. <i>Clinical Cancer Research</i> , 2005, 11, 6442-6449.	3.2	220
239	Azacitidine Induces Demethylation of the Epstein-Barr Virus Genome in Tumors. <i>Journal of Clinical Oncology</i> , 2004, 22, 1373-1381.	0.8	129
240	Phase II Trial of Infusional Cyclophosphamide, Doxorubicin, and Etoposide in Patients With HIV-Associated Non-Hodgkin's Lymphoma: An Eastern Cooperative Oncology Group Trial (E1494). <i>Journal of Clinical Oncology</i> , 2004, 22, 1491-1500.	0.8	114
241	Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma. <i>Oncogene</i> , 2004, 23, 1326-1331.	2.6	63
242	Smoking and Hodgkin Lymphoma Risk in Women United States. <i>Cancer Causes and Control</i> , 2004, 15, 387-397.	0.8	30
243	Oral Valacyclovir as Prophylaxis against Herpes Simplex Virus Reactivation During High Dose Chemotherapy for Leukemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 2215-2219.	0.6	20
244	Inter- and Intra-Observer Reliability of Epstein-Barr Virus Detection in Hodgkin Lymphoma using Histochemical Procedures. <i>Leukemia and Lymphoma</i> , 2004, 45, 489-497.	0.6	21
245	Promoter hypermethylation of the cyclin-dependent kinase inhibitor (CDKI) gene p21WAF1/CIP1/SDI1 is rare in various lymphomas and carcinomas. <i>Blood</i> , 2004, 103, 743-746.	0.6	33
246	Outcomes of Autologous and Allogeneic BMT for Mantle Cell Lymphoma.. <i>Blood</i> , 2004, 104, 901-901.	0.6	1
247	Posttransplant lymphoproliferative disease: Pathogenesis, monitoring, and therapy. <i>Current Oncology Reports</i> , 2003, 5, 359-363.	1.8	8
248	Viruses as potential targets for therapy in HIV-associated malignancies. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 697-702.	0.9	7
249	Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998. <i>Cancer</i> , 2003, 98, 300-309.	2.0	96
250	Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 312-319.	2.0	31
251	Infection and Lymphoma. <i>New England Journal of Medicine</i> , 2003, 349, 1309-1311.	13.9	19
252	Virus as master of the house. <i>Blood</i> , 2003, 102, 3861-3862.	0.6	0

#	ARTICLE	IF	CITATIONS
253	Epstein-Barr virus-associated lymphoproliferative disorders. <i>Reviews in Clinical and Experimental Hematology</i> , 2003, 7, 362-74.	0.1	9
254	Guidelines for Interpreting EBER In Situ Hybridization and LMP1 Immunohistochemical Tests for Detecting Epstein-Barr Virus in Hodgkin Lymphoma. <i>American Journal of Clinical Pathology</i> , 2002, 117, 259-267.	0.4	138
255	Patterns of Gene Expression and a Transactivation Function Exhibited by the vGCR (ORF74) Chemokine Receptor Protein of Kaposi's Sarcoma-Associated Herpesvirus. <i>Journal of Virology</i> , 2002, 76, 3421-3439.	1.5	135
256	Epstein-Barr virus DNA in body fluids. <i>Current Opinion in Oncology</i> , 2002, 14, 533-537.	1.1	14
257	Plasma cell dyscrasia, Hodgkin lymphoma, HIV, and Kaposi sarcoma-associated herpesvirus. <i>Current Opinion in Oncology</i> , 2002, 14, 543-545.	1.1	9
258	Conservation of Epstein-Barr Virus Cytotoxic T-Cell Epitopes in Posttransplant Lymphomas. <i>American Journal of Pathology</i> , 2002, 160, 1839-1845.	1.9	13
259	Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease. <i>Journal of Medical Virology</i> , 2002, 68, 370-377.	2.5	29
260	Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience. <i>British Journal of Haematology</i> , 2002, 117, 907-913.	1.2	17
261	Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 561-567.	2.0	22
262	Long-Term Results of Blood and Marrow Transplantation for Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2001, 19, 4314-4321.	0.8	163
263	Chemotherapy for Human Immunodeficiency Virus-Associated Non-Hodgkin's Lymphoma in Combination With Highly Active Antiretroviral Therapy. <i>Journal of Clinical Oncology</i> , 2001, 19, 2171-2178.	0.8	264
264	Epstein-Barr virus and survival after Hodgkin disease in a population-based series of women. <i>Cancer</i> , 2001, 91, 1579-1587.	2.0	55
265	Spindle Cell Conversion by Kaposi's Sarcoma-Associated Herpesvirus: Formation of Colonies and Plaques with Mixed Lytic and Latent Gene Expression in Infected Primary Dermal Microvascular Endothelial Cell Cultures. <i>Journal of Virology</i> , 2001, 75, 5614-5626.	1.5	178
266	Linkage between STAT Regulation and Epstein-Barr Virus Gene Expression in Tumors. <i>Journal of Virology</i> , 2001, 75, 2929-2937.	1.5	132
267	Induction of Epstein-Barr Virus Kinases To Sensitize Tumor Cells to Nucleoside Analogues. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2082-2091.	1.4	97
268	New controversies and new directions. <i>Current Opinion in Oncology</i> , 2000, 12, 435-437.	1.1	0
269	Application of the ELISPOT assay to the characterization of CD8+ responses to Epstein-Barr virus antigens. <i>Blood</i> , 2000, 95, 241-248.	0.6	92
270	Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. <i>Blood</i> , 2000, 96, 4055-4063.	0.6	167

#	ARTICLE	IF	CITATIONS
271	A New Primary Effusion Lymphoma-Derived Cell Line Yields a Highly Infectious Kaposi's Sarcoma Herpesvirus-Containing Supernatant. <i>Journal of Virology</i> , 2000, 74, 10187-10193.	1.5	147
272	Gammaherpesviruses and "Hit-and-Run" Oncogenesis. <i>American Journal of Pathology</i> , 2000, 156, 1-3.	1.9	131
273	Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 628-632.	2.0	98
274	Application of the ELISPOT assay to the characterization of CD8+ responses to Epstein-Barr virus antigens. <i>Blood</i> , 2000, 95, 241-248.	0.6	16
275	Human Herpesvirus 8-Encoded Thymidine Kinase and Phosphotransferase Homologues Confer Sensitivity to Ganciclovir. <i>Journal of Virology</i> , 1999, 73, 4786-4793.	1.5	91
276	Expression of Epstein-Barr Virus BamHI-A Rightward Transcripts in Latently Infected B Cells From Peripheral Blood. <i>Blood</i> , 1999, 93, 3026-3032.	0.6	74
277	DNA methylation and the Epstein-Barr virus. <i>Seminars in Cancer Biology</i> , 1999, 9, 369-375.	4.3	82
278	Serum sCD23 Level in Patients with AIDS-Related Non-Hodgkin's Lymphoma Is Associated with Absence of Epstein-Barr Virus in Tumor Tissue. <i>Clinical Immunology</i> , 1999, 93, 239-244.	1.4	12
279	Methylation Status of the Epstein-Barr Virus Major Latent Promoter C in Iatrogenic B Cell Lymphoproliferative Disease. <i>American Journal of Pathology</i> , 1999, 155, 619-625.	1.9	100
280	PCR Detection of Adenovirus in a Bone Marrow Transplant Recipient: Hemorrhagic Cystitis as a Presenting Manifestation of Disseminated Disease. <i>Journal of Clinical Microbiology</i> , 1999, 37, 686-689.	1.8	57
281	Comparison of Genetic Variability at Multiple Loci across the Genomes of the Major Subtypes of Kaposi's Sarcoma-Associated Herpesvirus Reveals Evidence for Recombination and for Two Distinct Types of Open Reading Frame K15 Alleles at the Right-Hand End. <i>Journal of Virology</i> , 1999, 73, 6646-6660.	1.5	189
282	Epstein-barr virus detection in nasopharyngeal tissues of patients with suspected nasopharyngeal carcinoma. <i>Cancer</i> , 1998, 82, 1449-1453.	2.0	59
283	Absence of Epstein-Barr virus EBER-1 transcripts in an epidemiologically diverse group of breast cancers. , 1998, 75, 555-558.		77
284	Feasibility of Cellular Adoptive Immunotherapy for Epstein-Barr Virus-Associated Lymphomas Using Haploidentical Donors. <i>Stem Cells and Development</i> , 1998, 7, 257-261.	1.0	31
285	AIDS oncology. <i>Current Opinion in Infectious Diseases</i> , 1998, 11, 23-28.	1.3	1
286	Epstein-Barr Virus (EBV) in Endemic Burkitt's Lymphoma: Molecular Analysis of Primary Tumor Tissue. <i>Blood</i> , 1998, 91, 1373-1381.	0.6	169
287	Epstein-barr virus detection in nasopharyngeal tissues of patients with suspected nasopharyngeal carcinoma. , 1998, 82, 1449.		1
288	The Epstein-Barr Virus Major Latent Promoter Qp Is Constitutively Active, Hypomethylated, and Methylation Sensitive. <i>Journal of Virology</i> , 1998, 72, 7075-7083.	1.5	69

#	ARTICLE	IF	CITATIONS
289	Human herpesvirus-8. <i>Current Opinion in Oncology</i> , 1997, 9, 440-449.	1.1	13
290	Methylation of the Epstein-Barr Virus Genome in Normal Lymphocytes. <i>Blood</i> , 1997, 90, 4480-4484.	0.6	60
291	Epstein-Barr virus-associated Hodgkin's disease: Epidemiologic characteristics in international data. , 1997, 70, 375-382.		424
292	Epstein-Barr virus-associated Hodgkin's disease: Epidemiologic characteristics in international data. , 1997, 70, 375.		4
293	AIDS primary central nervous system lymphoma. <i>Current Opinion in Oncology</i> , 1996, 8, 373-376.	1.1	43
294	AIDS oncology emerges as a clinical discipline. <i>Current Opinion in Oncology</i> , 1996, 8, 371-372.	1.1	0
295	Epstein-Barr virus and bone marrow transplantation. <i>Current Opinion in Oncology</i> , 1995, 7, 102-106.	1.1	14
296	Cancer in AIDS. <i>Current Opinion in Oncology</i> , 1995, 7, 427-428.	1.1	0
297	Epstein-Barr Virus Is Infrequently Identified in Non-Hodgkin's Lymphomas Associated with Hodgkin's Disease. <i>American Journal of Surgical Pathology</i> , 1994, 18, 48-61.	2.1	85
298	Rapid in situ hybridization for the diagnosis of latent Epstein-Barr virus infection. <i>Molecular and Cellular Probes</i> , 1993, 7, 105-109.	0.9	60
299	t(11;18)(q21;q21) is a recurrent chromosome abnormality in small lymphocytic lymphoma. <i>Genes Chromosomes and Cancer</i> , 1992, 4, 153-157.	1.5	45
300	Biology of the lymphomas. <i>Current Opinion in Oncology</i> , 1991, 3, 806-812.	1.1	6
301	Recent experimental studies in lymphoma. <i>Current Opinion in Oncology</i> , 1990, 2, 811-815.	1.1	0
302	Detection of ebv gene expression in reed-sternberg cells of Hodgkin's disease. <i>International Journal of Cancer</i> , 1990, 46, 801-804.	2.3	272
303	Oligonucleotides for polymerase chain reaction amplification and hybridization detection of Epstein-Barr virus DNA in clinical specimens. <i>Molecular and Cellular Probes</i> , 1990, 4, 397-407.	0.9	43
304	A Survey of Epstein-Barr Virus DNA in Lymphoid Tissue: Frequent Detection in Hodgkin's Disease. <i>American Journal of Clinical Pathology</i> , 1989, 91, 1-5.	0.4	206
305	Localized Herpes Simplex Lymphadenitis. <i>American Journal of Clinical Pathology</i> , 1986, 86, 444-448.	0.4	36
306	Autologous Bone Marrow Transplantation in Patients with Acute Nonlymphocytic Leukemia, Using ex Vivo Marrow Treatment with 4-Hydroperoxycyclophosphamide. <i>New England Journal of Medicine</i> , 1986, 315, 141-147.	13.9	431

#	ARTICLE	IF	CITATIONS
307	Structural Organization of Human Herpesvirus DNA Molecules. Journal of Investigative Dermatology, 1984, 83, S29-S41.	0.3	14
308	Acyclovir Halts Progression of Herpes Zoster in Immunocompromised Patients. New England Journal of Medicine, 1983, 308, 1448-1453.	13.9	437
309	Epstein-Barr Virus Infection. , 0, , 1410-1418.		0